| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.6 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | ETP-46464 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.6 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.028 | 0.6 |